NOVAVAX INC Research and Development Expense
NOVAVAX INC (NVAX) reported Research and Development Expense of $70.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- NOVAVAX INC research and development expense for the quarter ending 2026-06-30 was $70.69M, a 10.78% decline year-over-year.
- NOVAVAX INC research and development expense for the quarter ending 2026-03-31 was $95.47M, a 7.35% increase year-over-year.
- NOVAVAX INC research and development expense for the quarter ending 2025-12-31 was $75.88M, a 27.31% decline year-over-year.
- NOVAVAX INC research and development expense for the quarter ending 2025-09-30 was $98.27M, a 12.75% increase year-over-year.
- NOVAVAX INC research and development expense for fiscal 2025 was $342.32M, a 12.49% decline from fiscal 2024.
- NOVAVAX INC research and development expense for fiscal 2024 was $391.17M, a 46.96% decline from fiscal 2023.
- NOVAVAX INC research and development expense for fiscal 2023 was $737.50M, a 40.30% decline from fiscal 2022.
- NOVAVAX INC research and development expense for fiscal 2022 was $1.24B, a 51.26% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $70.69M 10-Q · filed 2026-08-06 | $166.16M 10-Q · filed 2026-08-06 | $242.04M derived: sum of 3 quarters · filed 2026-08-06 | $340.31M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $95.47M 10-Q · filed 2026-05-06 | $171.35M derived: sum of 2 quarters · filed 2026-05-06 | $269.62M derived: sum of 3 quarters · filed 2026-05-06 | $348.86M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $75.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $174.15M derived: sum of 2 quarters · filed 2026-02-26 | $253.38M derived: sum of 3 quarters · filed 2026-08-06 | $342.32M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $98.27M 10-Q · filed 2025-11-06 | $177.51M derived: sum of 2 quarters · filed 2026-08-06 | $266.44M 10-Q · filed 2025-11-06 | $370.82M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $79.23M 10-Q · filed 2026-08-06 | $168.17M 10-Q · filed 2026-08-06 | $272.55M derived: sum of 3 quarters · filed 2026-08-06 | $359.71M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $88.94M 10-Q · filed 2026-05-06 | $193.32M derived: sum of 2 quarters · filed 2026-05-06 | $280.48M derived: sum of 3 quarters · filed 2026-05-06 | $387.43M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $104.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $191.54M derived: sum of 2 quarters · filed 2026-02-26 | $298.49M derived: sum of 3 quarters · filed 2026-02-26 | $391.17M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $87.16M 10-Q · filed 2025-11-06 | $194.11M derived: sum of 2 quarters · filed 2025-11-06 | $286.79M 10-Q · filed 2025-11-06 | $451.49M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $106.95M 10-Q · filed 2025-08-06 | $199.63M 10-Q · filed 2025-08-06 | $364.32M derived: sum of 3 quarters · filed 2026-02-26 | $470.55M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $92.68M 10-Q · filed 2025-05-08 | $257.38M derived: sum of 2 quarters · filed 2026-02-26 | $363.61M derived: sum of 3 quarters · filed 2026-02-26 | $583.08M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $164.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $270.93M derived: sum of 2 quarters · filed 2026-02-26 | $490.40M derived: sum of 3 quarters · filed 2026-02-26 | $737.50M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $106.23M 10-Q · filed 2024-11-12 | $325.70M derived: sum of 2 quarters · filed 2024-11-12 | $572.80M 10-Q · filed 2024-11-12 | $830.65M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $219.47M 10-Q · filed 2024-08-08 | $466.58M 10-Q · filed 2024-08-08 | $724.43M derived: sum of 3 quarters · filed 2025-02-27 | $1.03B derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | $247.10M 10-Q · filed 2024-05-10 | $504.95M derived: sum of 2 quarters · filed 2025-02-27 | $809.25M derived: sum of 3 quarters · filed 2025-02-27 | $1.10B derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $257.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $562.15M derived: sum of 2 quarters · filed 2025-02-27 | $851.79M derived: sum of 3 quarters · filed 2025-02-27 | $1.24B 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $304.30M 10-Q · filed 2023-11-09 | $593.95M derived: sum of 2 quarters · filed 2023-11-09 | $977.43M 10-Q · filed 2023-11-09 | $1.94B derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | $289.65M 10-Q · filed 2023-08-08 | $673.13M 10-Q · filed 2023-08-08 | $1.64B derived: sum of 3 quarters · filed 2024-02-28 | $2.04B derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | $383.48M 10-Q · filed 2023-05-09 | $1.35B derived: sum of 2 quarters · filed 2024-02-28 | $1.75B derived: sum of 3 quarters · filed 2024-02-28 | $2.33B derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | $962.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.37B derived: sum of 2 quarters · filed 2024-02-28 | $1.94B derived: sum of 3 quarters · filed 2024-02-28 | $2.53B 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $408.19M 10-Q · filed 2022-11-09 | $978.88M derived: sum of 2 quarters · filed 2022-11-09 | $1.57B 10-Q · filed 2022-11-09 | $1.97B derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $570.68M 10-Q · filed 2022-08-09 | $1.16B 10-Q · filed 2022-08-09 | $1.56B derived: sum of 3 quarters · filed 2023-02-28 | $1.86B derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $592.67M 10-Q · filed 2022-05-10 | $993.87M derived: sum of 2 quarters · filed 2023-02-28 | $1.29B derived: sum of 3 quarters · filed 2023-02-28 | $1.32B derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $401.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $695.29M derived: sum of 2 quarters · filed 2023-02-28 | $730.13M derived: sum of 3 quarters · filed 2023-02-28 | $747.03M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $294.09M 10-Q · filed 2021-11-05 | $328.93M derived: sum of 2 quarters · filed 2021-11-05 | $345.83M 10-Q · filed 2021-11-05 | $375.17M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $34.85M 10-Q · filed 2021-08-05 | $51.74M 10-Q · filed 2021-08-05 | $81.08M derived: sum of 3 quarters · filed 2022-03-01 | $99.69M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $16.89M 10-Q · filed 2021-05-10 | $46.23M derived: sum of 2 quarters · filed 2022-03-01 | $64.85M derived: sum of 3 quarters · filed 2022-03-01 | $95.26M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $29.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $47.95M derived: sum of 2 quarters · filed 2022-03-01 | $78.37M derived: sum of 3 quarters · filed 2022-03-01 | $113.84M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $18.61M 10-Q · filed 2020-11-10 | $49.03M derived: sum of 2 quarters · filed 2020-11-10 | $84.50M 10-Q · filed 2020-11-10 | $127.92M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $30.42M 10-Q · filed 2020-08-10 | $65.89M 10-Q · filed 2020-08-10 | $109.31M derived: sum of 3 quarters · filed 2021-03-01 | $150.63M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $35.47M 10-Q · filed 2020-05-11 | $78.89M derived: sum of 2 quarters · filed 2021-03-01 | $120.21M derived: sum of 3 quarters · filed 2021-03-01 | $164.76M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $43.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $84.74M derived: sum of 2 quarters · filed 2021-03-01 | $129.28M derived: sum of 3 quarters · filed 2021-03-01 | $173.80M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $41.33M 10-Q · filed 2019-11-07 | $85.87M derived: sum of 2 quarters · filed 2019-11-07 | $130.38M 10-Q · filed 2019-11-07 | $180.04M derived: sum of 4 quarters · filed 2020-03-11 | ||||
| 2018-06-30 | $44.54M 10-Q · filed 2019-08-07 | $89.06M 10-Q · filed 2019-08-07 | $138.71M derived: sum of 3 quarters · filed 2020-03-11 | $180.57M derived: sum of 4 quarters · filed 2020-03-11 | ||||
| 2018-03-31 | $44.51M 10-Q · filed 2019-05-02 | $94.17M derived: sum of 2 quarters · filed 2020-03-11 | $136.03M derived: sum of 3 quarters · filed 2020-03-11 | $175.29M derived: sum of 4 quarters · filed 2020-03-11 | ||||
| 2017-12-31 | $49.66M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $91.52M derived: sum of 2 quarters · filed 2020-03-11 | $130.78M derived: sum of 3 quarters · filed 2020-03-11 | $168.44M 10-K · filed 2020-03-11 | ||||
| 2017-09-30 | $41.86M 10-Q · filed 2018-11-07 | $81.13M derived: sum of 2 quarters · filed 2018-11-07 | $118.78M 10-Q · filed 2018-11-07 | $169.88M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-06-30 | $39.26M 10-Q · filed 2018-08-08 | $76.92M 10-Q · filed 2018-08-08 | $128.02M derived: sum of 3 quarters · filed 2019-03-18 | $181.00M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-03-31 | $37.65M 10-Q · filed 2018-05-09 | $88.75M derived: sum of 2 quarters · filed 2019-03-18 | $141.74M derived: sum of 3 quarters · filed 2019-03-18 | $206.64M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2016-12-31 | $51.10M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $104.08M derived: sum of 2 quarters · filed 2019-03-18 | $168.99M derived: sum of 3 quarters · filed 2019-03-18 | $237.94M 10-K · filed 2019-03-18 | ||||
| 2016-09-30 | $52.98M 10-Q · filed 2017-11-07 | $117.89M derived: sum of 2 quarters · filed 2017-11-07 | $186.84M 10-Q · filed 2017-11-07 | $262.74M derived: sum of 4 quarters · filed 2018-03-14 | ||||
| 2016-06-30 | $64.90M 10-Q · filed 2017-08-08 | $133.86M 10-Q · filed 2017-08-08 | $209.76M derived: sum of 3 quarters · filed 2018-03-14 | $240.42M derived: sum of 4 quarters · filed 2018-03-14 | ||||
| 2016-03-31 | $68.95M 10-Q · filed 2017-05-08 | $144.86M derived: sum of 2 quarters · filed 2018-03-14 | $175.52M derived: sum of 3 quarters · filed 2018-03-14 | $203.25M derived: sum of 4 quarters · filed 2018-03-14 | ||||
| 2015-12-31 | $75.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $106.57M derived: sum of 2 quarters · filed 2018-03-14 | $134.30M derived: sum of 3 quarters · filed 2018-03-14 | $162.64M 10-K · filed 2018-03-14 | ||||
| 2015-09-30 | $30.66M 10-Q · filed 2016-11-09 | $27.92M 10-Q · filed 2015-11-09 | $58.39M derived: sum of 2 quarters · filed 2016-11-09 | $86.74M 10-Q · filed 2016-11-09 | $78.69M 10-Q · filed 2015-11-09 | $132.22M derived: sum of 4 quarters · filed 2017-02-27 | ||
| 2015-06-30 | $27.73M 10-Q · filed 2016-08-09 | $25.04M 10-Q · filed 2015-08-10 | $56.08M 10-Q · filed 2016-08-09 | $50.77M 10-Q · filed 2015-08-10 | $101.56M derived: sum of 3 quarters · filed 2017-02-27 | $120.78M derived: sum of 4 quarters · filed 2017-02-27 | ||
| 2015-03-31 | $28.35M 10-Q · filed 2016-05-05 | $25.89M 10-Q · filed 2015-05-07 | $73.83M derived: sum of 2 quarters · filed 2017-02-27 | $93.05M derived: sum of 3 quarters · filed 2017-02-27 | $108.25M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2014-12-31 | $45.48M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $64.70M derived: sum of 2 quarters · filed 2017-02-27 | $79.90M derived: sum of 3 quarters · filed 2017-02-27 | $94.42M 10-K · filed 2017-02-27 | $79.44M 10-K · filed 2015-02-27 | |||
| 2014-09-30 | $19.22M 10-Q · filed 2015-11-09 | $34.42M derived: sum of 2 quarters · filed 2015-11-09 | $48.94M 10-Q · filed 2015-11-09 | $73.48M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $15.20M 10-Q · filed 2015-08-10 | $29.72M 10-Q · filed 2015-08-10 | $54.26M derived: sum of 3 quarters · filed 2016-02-29 | $68.21M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $14.52M 10-Q · filed 2015-05-07 | $39.06M derived: sum of 2 quarters · filed 2016-02-29 | $53.01M derived: sum of 3 quarters · filed 2016-02-29 | $63.79M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $24.54M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $38.49M derived: sum of 2 quarters · filed 2016-02-29 | $49.27M derived: sum of 3 quarters · filed 2016-02-29 | $58.53M 10-K · filed 2016-02-29 | $50.31M 10-K · filed 2014-03-12 | |||
| 2013-09-30 | $13.95M 10-Q · filed 2014-11-06 | $24.73M derived: sum of 2 quarters · filed 2014-11-06 | $33.99M 10-Q · filed 2014-11-06 | $43.63M derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2013-06-30 | $10.79M 10-Q · filed 2014-08-07 | $20.04M 10-Q · filed 2014-08-07 | $29.68M derived: sum of 3 quarters · filed 2015-02-27 | $36.32M derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2013-03-31 | $9.26M 10-Q · filed 2014-05-08 | $9.43M 10-Q · filed 2013-05-09 | $18.89M derived: sum of 2 quarters · filed 2015-02-27 | $25.54M derived: sum of 3 quarters · filed 2015-02-27 | $30.91M derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2012-12-31 | $9.64M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $16.28M derived: sum of 2 quarters · filed 2015-02-27 | $21.65M derived: sum of 3 quarters · filed 2015-02-27 | $26.91M 10-K · filed 2015-02-27 | $26.06M 10-K · filed 2013-03-12 | |||
| 2012-09-30 | $6.64M 10-Q · filed 2013-11-12 | $6.39M 10-Q · filed 2012-11-09 | $12.01M derived: sum of 2 quarters · filed 2013-11-12 | $17.27M 10-Q · filed 2013-11-12 | $16.65M 10-Q · filed 2012-11-09 | $22.24M derived: sum of 4 quarters · filed 2014-03-12 | ||
| 2012-06-30 | $5.37M 10-Q · filed 2013-08-08 | $5.18M 10-Q · filed 2012-08-09 | $10.63M 10-Q · filed 2013-08-08 | $10.25M 10-Q · filed 2012-08-09 | $15.60M derived: sum of 3 quarters · filed 2014-03-12 | $19.65M derived: sum of 4 quarters · filed 2014-03-12 | ||
| 2012-03-31 | $5.34M 10-Q · filed 2013-05-09 | $5.08M 10-Q · filed 2012-05-09 | $10.23M derived: sum of 2 quarters · filed 2014-03-12 | $14.28M derived: sum of 3 quarters · filed 2014-03-12 | $18.63M derived: sum of 4 quarters · filed 2014-03-12 | |||
| 2011-12-31 | $4.89M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $8.94M derived: sum of 2 quarters · filed 2014-03-12 | $13.29M derived: sum of 3 quarters · filed 2014-03-12 | $18.36M 10-K · filed 2014-03-12 | $17.89M 10-K · filed 2012-03-14 | |||
| 2011-09-30 | $4.05M 10-Q · filed 2012-11-09 | $6.24M 10-Q · filed 2011-11-08 | $8.40M derived: sum of 2 quarters · filed 2012-11-09 | $13.47M 10-Q · filed 2012-11-09 | $17.24M 10-Q · filed 2011-11-08 | $18.28M derived: sum of 4 quarters · filed 2013-03-12 | ||
| 2011-06-30 | $4.35M 10-Q · filed 2012-08-09 | $5.58M 10-Q · filed 2011-08-09 | $9.42M 10-Q · filed 2012-08-09 | $11.00M 10-Q · filed 2011-08-09 | $14.23M derived: sum of 3 quarters · filed 2013-03-12 | $22.10M derived: sum of 4 quarters · filed 2013-03-12 | ||
| 2011-03-31 | $5.07M 10-Q · filed 2012-05-09 | $9.88M derived: sum of 2 quarters · filed 2013-03-12 | $17.75M derived: sum of 3 quarters · filed 2013-03-12 | $24.07M derived: sum of 4 quarters · filed 2013-03-12 | ||||
| 2010-12-31 | $4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $12.68M derived: sum of 2 quarters · filed 2013-03-12 | $19.00M derived: sum of 3 quarters · filed 2013-03-12 | $28.03M 10-K · filed 2013-03-12 | ||||
| 2010-09-30 | $7.87M 10-Q · filed 2011-11-08 | $14.20M derived: sum of 2 quarters · filed 2011-11-08 | $23.23M 10-Q · filed 2011-11-08 | |||||
| 2010-06-30 | $6.33M 10-Q · filed 2011-08-09 | $15.36M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | $25.78M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |